Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.67 |
| ▸ | RET | P07949 | 5/20 | 0.67 |
| ▸ | FLT3 | P36888 | 5/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.67 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | FLT1 | P17948 | 5/20 | 0.63 |
| ▸ | AURKA | O14965 | 4/20 | 0.63 |
| ▸ | CSF1R | P07333 | 3/20 | 0.63 |
| ▸ | SRC | P12931 | 3/20 | 0.63 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.63 |
| ▸ | FLT4 | P35916 | 3/20 | 0.63 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.63 |
| ▸ | STK3 | Q13188 | 3/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.63 |
| ▸ | PLK4 | O00444 | 2/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465253 | 1.00 | KDR (1.00) | KDRFGFR1RETFLT3PDGFRB | |
| SCHEMBL5469616 | 0.89 | KDR (0.81) | KDRFGFR1RETFLT3PDGFRB | |
| SCHEMBL5469611 | 0.89 | KDR (0.81) | KDRFGFR1RETFLT3PDGFRB | |
| SCHEMBL2117299 | 0.89 | KDR (0.80) | KDRFGFR1RETFLT3PDGFRB | |
| SCHEMBL2117305 | 0.89 | KDR (0.80) | KDRFGFR1RETFLT3PDGFRB | |
| SCHEMBL2114412 | 0.86 | KDR (0.76) | KDRFGFR1RETFLT3PDGFRB | |
| SCHEMBL31672431 | 0.86 | KDR (0.76) | KDRFGFR1RETFLT3PDGFRB | |
| SCHEMBL2114413 | 0.86 | KDR (0.76) | KDRFGFR1RETFLT3PDGFRB | |
| SCHEMBL5480552 | 0.86 | KDR (0.75) | KDRFGFR1RETFLT3PDGFRB | |
| SCHEMBL5480551 | 0.86 | KDR (0.75) | KDRFGFR1RETFLT3PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | KDR 4334/4885FGFR1 4752/4885RET 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.